Treatment Outcomes Of Fluticasone Propionate

There are no cure for this disease. However, there are different treatment to prevent further deterioration of the lungs function in order to improve the quality of life of the patient by increasing capacity of their physical activity. One of the main severe complication a patient with COPD can develop is exacerbation. Increased breathlessness, increased sputum volume and purulent sputum are the signs and symptoms of exacerbation. Early detection of the signs of exacerbation can help keep the condition of the patient from worsening. The treatments of COPD mainly aims at controlling the symptoms of exacerbation such as taking inhalers. Patients who are over the age of 35 and ex-smokers with chronic cough and bronchitis are recommended to have spirometer (NICE, 2004). This is because it is possible to delay or prevent patients from developing severe case of COPD is identified before they lose their lungs functions. Oxygen therapy is another treatment for COPD as the patients with this condition has high

The study began with 32 patients having stages II to IV COPD. They had to meet the criteria pertaining to the Global Initiative for Chronic Obstructive Pulmonary Disease; total lung capacity >120%, (FEV1/FVC) <70%, FEV1 <80%, RV/TLC >140% and >40% of predicted values in stable conditions. Patients were removed from the study if they had asthma, heart failure, orthopedic impairments of the shoulder girdle, recent surgery, past thoracic fractures, pneumothorax, and claustrophobia.

Moderately severe. At this COPD stage, the limitation of airflow begins to worsen and is easy to see on a spirometry test. Symptoms like coughing and sputum production will begin to increase, most people don’t even know they have a problem at this stage. Severe COPD almost always has a noticeable impact on your quality of life. Breathing function continues to decline. Very severe. At this level of COPD, quality of life is often extremely affected. Breathing difficulties can even be life-threatening, and the lack of airflow coming into the lungs starts to affect the heart and circulatory system. COPD affects over 24 million Americans and our community stretches across all 50 states. 2013 marks the first year ever that we are able to see the COPD prevalence rate for all 50 states thanks to the new data put forth by the Centers for Disease Control and Prevention’s Behavior Risk Surveillance Survey, which is the nation’s largest telephone health

The study included 100 patients with COPD. All patients fulfilled the inclusion and exclusion criteria. According to its demographic and clinical parameters and treatment groups differ among themselves. Completed the study, all patients included in the study. The therapy in all patients with a clinically meaningful improvement of symptoms was observed.

Chronic obstructive pulmonary disease (COPD) is major leading cause of morbidity and mortality in United States. There are some risk factors for COPD like age and smoking and other illnesses, often leading COPD patients to present with multiple coexisting comorbidities. COPD exacerbations and comorbidities plays a major role in the overall severity in individual’s health. The management and the medical intervention in COPD patients with comorbidities need a holistic approach. All of the health care specialists in COPD management need to work together with professionals specialized in the management of the other chronic diseases in order to provide a multidisciplinary approach to COPD patients with multiple diseases. A patient M. A. 72 years

The GOLD Science Committee reviews published research on COPD management and prevention to evaluate the impact of this research on recommendations; members of the Committee are recognized leaders in COPD research and clinical practice

Rationale: L.J. exhibits symptoms of COPD that include shortness of breath and productive cough. He has a smoking history of 65-pack-year and smoking has been identified as the primary cause/trigger of the disease (Nagelmann et al., 2011).

NICE COPD guidelines have made specific recommendations regarding the use of inhaled long-acting bronchodilators and inhaled steroids separately and in combination, but newer studies have assessed these drugs singly and in combination over longer periods of time.

Diagnosing COPD is multifactorial, as stated previously, an all-encompassing nursing assessment and patient history must be conducted. When these processes are finalized, and subjective evidence points towards COPD, it is necessary to confirm the diagnosis with objective data. The definitive way to do this is by conducting pulmonary function testing (PFT); specifically, spirometry. On top of diagnosing, spirometry, is also pertinent for staging the patients COPD (Corbridge,et al., 2012). In addition to these facets, there are several other radiologic and laboratory tests that are helpful in determining the severity of COPD; they are not so much diagnostic, as they are informative.

BB, 86, presented to EMCH with pneumonia and a history of COPD and heart failure. The chief complaint for admission was shortness of breath and chest pain. She was put on many medications to help her conditions. A patient with COPD has weakened lungs already so getting control over her pneumonia was that much more important. General overall health is key to preventing infections in COPD patients (Faris, 2012).

As of not long ago, the significant objective of COPD treatment was the diminishment of side effects. Nonetheless, with the acknowledgment that intensifications of COPD are extremely normal, have a noteworthy antagonistic effect on personal satisfaction, and may speed sickness movement, rules and clinical consideration are concentrating on decreasing future dangers, for example, the counteractive action and treatment of intensifications (2013, August 23). In created nations the hospitalization of COPD patients, brought on transcendently by intensifications, represents over half of direct human services

Causes of COPD are, but are not limited to, tobacco smoke, occupational working exposure, outdoor and indoor pollutants, genetic factors and early life environmental factors. This disease has become the third leading cause of death in the United States of America. The only proven way to slow the progression is to QUIT smoking. Some studies have shown that giving a bronchodilator has reversed some lung function which benefits the patient. Symptoms of COPD include, but are not limited to, dyspnea upon exertion, chronic cough with or without phlegm, fatigue and weight loss. Some common characteristics of COPD are exacerbations and episodes of acute worsening. Exacerbations are commonly caused by viral and/or bacterial infections and pollution. Multimodal treatments are used and include

COPD, or Chronic Obstructive Pulmonary Disease, is one of the most common lung diseases. Thousands of people are diagnosed every year, and it recently moved up to the 3rd leading cause of death in the U.S., behind heart disease and cancer. This paper will discuss disease pathology, the most common and recently discovered diagnostic tests, as well as treatment options. It will also address end of life care.

According to the Centers for Disease Control and Prevention (CDC), COPD is the fourth leading cause of death in the United States. Approximately 12 million people in the United States have been diagnosed with COPD. Many more may be affected and don’t know they have it. Its generality increases with age. Men are more likely to have the disease, but the death rate for men and women is the same (2014).

Unfortunately, there is currently no cure for COPD, but there are medications that are available to help the symptoms and make it easier for the person to breathe. Bronchodilators are a type of medication that will help open the airways to get better airflow. Short acting bronchodilators are used in emergency situations for rapid relief. Some short acting bronchodilators are Albuterol, levalbuterol (Xopenex), and Ipratropium (Atrovent). They can come in an inhaler or in a liquid that can be inhaled from a nebulizer. There are some side effects to the short acting bronchodilators including dry mouth, blurred vision, tremors, tachycardia, or a cough. Long acting bronchodilators help treat the symptoms of COPD over a longer period of time, so it may take longer to see results. Patients can use long acting bronchodilators once or twice a day depended on how bad the symptoms are, which also comes in inhalers or a liquid that can be put in a nebulizer. Some examples of the medication are Tiotropium (Spiriva), Salmeterol (Serevent, Formoterol (Foradil, Perforomist), Arformoterol (Brovana), Indacaterol (Arcapta), Aclidinium (Tudorza). (Mayo Clinic Staff, 2015). Over time these medications will help if the person takes them continually. Long acting Bronchodilators are not used as emergency or rescue medication. Some of the side effects of these medications are dry mouth, dizziness, tremors, runny nose, an irritated or scratchy throat, allergic reactions, blurred vision, and